The studies will evaluate VolitionRx's Nu.Q colorectal cancer screening platform in symptomatic and asymptomatic subjects throughout Asia.
The deal makes Arrow the sole distributor for the DiaCarta ColoScape test in Italy, San Marino, and Vatican City.
With the California licensure, the company’s PCR-based Colvera colorectal cancer monitoring test is available in all US states except New York.
The firm said it will use the funds to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer.
The company has partnered with several major medical centers to recruit several thousand subjects to compare its test to current mainstays.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
The findings run counter to historical data and may provide fodder to reconsider current guideline recommendations on surveillance of colorectal cancer patients.
The companies have signed a deal under which each will make its tests available to the other's customer base.
The privately held Cambridge, UK-based company announced earlier this month that it had raised an additional £11 million to support the commercialization of its platform.
The firm priced its offering at $2.40 per share and expects to raise $8.4 million in gross proceeds. It plans to use the funds for product development, clinical studies, and product development.